Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line

Rosa Mangerini, Francesca Argellati, Ulrich Pfeffer, Francesco Boccardo

Research output: Contribution to journalArticle

Abstract

Background: Bicalutamide (BIC) is an alternative treatment to castration for advanced prostate cancer. Breast events are common adverse effects which can be effectively prevented by the concurrent administration of tamoxifen, a selective estrogen receptor modulator. Materials and Methods: We investigated the effects of BIC, 4-hydroxy Tamoxifen (4OHT), the active metabolite of tamoxifen, and their combination on the expression of a panel of genes implicated in prostate cancer development and progression in LNCaP cells stimulated with dihydrotestosterone. Results: Our findings confirm the anti-proliferative activity of BIC on LNCaP cell growth but also show the down-regulating function of this anti-androgen on the expression of genes involved in tumor proliferation and invasion [cyclins, caspases, epidermal growth factor (EGF)]. The combination with 4OHT exerts a synergistic effect on the downregulation of some genes involved in prostate cancer progression. Conclusion: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials.

Original languageEnglish
Pages (from-to)5323-5329
Number of pages7
JournalAnticancer Research
Volume32
Issue number12
Publication statusPublished - Dec 2012

Fingerprint

Androgens
Prostatic Neoplasms
Tamoxifen
Caspases
Gene Expression
Cell Line
Selective Estrogen Receptor Modulators
Cyclins
Dihydrotestosterone
Castration
B-Cell Lymphoma
Oncogenes
Epidermal Growth Factor
Genes
Breast
Down-Regulation
Growth
afimoxifene
bicalutamide
Neoplasms

Keywords

  • 4OH-Tamoxifen
  • Bicalutamide
  • LNCaP cells
  • Prostate cancer
  • Quantitative RT-PCR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line. / Mangerini, Rosa; Argellati, Francesca; Pfeffer, Ulrich; Boccardo, Francesco.

In: Anticancer Research, Vol. 32, No. 12, 12.2012, p. 5323-5329.

Research output: Contribution to journalArticle

@article{9f74597fd2794fe69d0adcbcec46f376,
title = "Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line",
abstract = "Background: Bicalutamide (BIC) is an alternative treatment to castration for advanced prostate cancer. Breast events are common adverse effects which can be effectively prevented by the concurrent administration of tamoxifen, a selective estrogen receptor modulator. Materials and Methods: We investigated the effects of BIC, 4-hydroxy Tamoxifen (4OHT), the active metabolite of tamoxifen, and their combination on the expression of a panel of genes implicated in prostate cancer development and progression in LNCaP cells stimulated with dihydrotestosterone. Results: Our findings confirm the anti-proliferative activity of BIC on LNCaP cell growth but also show the down-regulating function of this anti-androgen on the expression of genes involved in tumor proliferation and invasion [cyclins, caspases, epidermal growth factor (EGF)]. The combination with 4OHT exerts a synergistic effect on the downregulation of some genes involved in prostate cancer progression. Conclusion: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials.",
keywords = "4OH-Tamoxifen, Bicalutamide, LNCaP cells, Prostate cancer, Quantitative RT-PCR",
author = "Rosa Mangerini and Francesca Argellati and Ulrich Pfeffer and Francesco Boccardo",
year = "2012",
month = "12",
language = "English",
volume = "32",
pages = "5323--5329",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line

AU - Mangerini, Rosa

AU - Argellati, Francesca

AU - Pfeffer, Ulrich

AU - Boccardo, Francesco

PY - 2012/12

Y1 - 2012/12

N2 - Background: Bicalutamide (BIC) is an alternative treatment to castration for advanced prostate cancer. Breast events are common adverse effects which can be effectively prevented by the concurrent administration of tamoxifen, a selective estrogen receptor modulator. Materials and Methods: We investigated the effects of BIC, 4-hydroxy Tamoxifen (4OHT), the active metabolite of tamoxifen, and their combination on the expression of a panel of genes implicated in prostate cancer development and progression in LNCaP cells stimulated with dihydrotestosterone. Results: Our findings confirm the anti-proliferative activity of BIC on LNCaP cell growth but also show the down-regulating function of this anti-androgen on the expression of genes involved in tumor proliferation and invasion [cyclins, caspases, epidermal growth factor (EGF)]. The combination with 4OHT exerts a synergistic effect on the downregulation of some genes involved in prostate cancer progression. Conclusion: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials.

AB - Background: Bicalutamide (BIC) is an alternative treatment to castration for advanced prostate cancer. Breast events are common adverse effects which can be effectively prevented by the concurrent administration of tamoxifen, a selective estrogen receptor modulator. Materials and Methods: We investigated the effects of BIC, 4-hydroxy Tamoxifen (4OHT), the active metabolite of tamoxifen, and their combination on the expression of a panel of genes implicated in prostate cancer development and progression in LNCaP cells stimulated with dihydrotestosterone. Results: Our findings confirm the anti-proliferative activity of BIC on LNCaP cell growth but also show the down-regulating function of this anti-androgen on the expression of genes involved in tumor proliferation and invasion [cyclins, caspases, epidermal growth factor (EGF)]. The combination with 4OHT exerts a synergistic effect on the downregulation of some genes involved in prostate cancer progression. Conclusion: The observation that the expression of several genes [such as B-cell lymphoma-2 (BCL2), myelocytomatosis oncogene (MYC), caspases] is modulated midly-to-moderately, after 4OHT addition suggests that this combined approach in the clinical setting should be further investigated through appropriate trials.

KW - 4OH-Tamoxifen

KW - Bicalutamide

KW - LNCaP cells

KW - Prostate cancer

KW - Quantitative RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=84872570178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872570178&partnerID=8YFLogxK

M3 - Article

C2 - 23225433

AN - SCOPUS:84872570178

VL - 32

SP - 5323

EP - 5329

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -